# Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis

> **NCT06543992** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 22 (estimated)

## Conditions studied

- Leptomeningeal Metastasis of Breast Cancer

## Interventions

- **DRUG:** Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir

## Key facts

- **NCT ID:** NCT06543992
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-13
- **Primary completion:** 2026-12-13
- **Final completion:** 2026-12-13
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06543992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06543992, "Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06543992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*